# PTC Therapeutics Inc. (PTCT) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $68.12, market value $5.7 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). PTC Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.11**. A PEG of 0.11 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 4.9×**. Each dollar of revenue is priced at 4.9×.
- **EV / EBITDA: 23.9×**. Enterprise value is 23.9× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 0.0%** (5-yr avg -5.2%). Free cash flow equals 0.0% of the market value, above its five-year average of -5.2%, so the shares are cheaper on cash than they have usually been.

## Profitability
- **Operating margin: 12.8%**. 12.8% of revenue is left after running the business.
- **Net margin: 39.4%**. 39.4% of each dollar of sales reaches the bottom line.
- **Return on equity: -332.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -12.9%**. Return on all capital, debt included, is -12.9%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -3.7%**. Each dollar of assets produces -3.7% of profit.

## Growth
- **Revenue growth (1 yr): 114.5%** (3-yr 35.3%/yr, 5-yr 35.4%/yr). Revenue grew 114.5% over the last year, against 35.4% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 264.5%**. Earnings per share rose 264.5%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Net debt / EBITDA: net cash**. PTC Therapeutics Inc. holds more cash than debt.
- **Current ratio: 2.35** (quick 2.35). Current assets cover the next year's liabilities 2.35 times.
- **Altman Z-score: 3.13**. A Z-score of 3.13 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. PTC Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (15 analysts). 15 analysts cover PTC Therapeutics Inc.; the consensus is buy, with an average price target of $100.40 (+47% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -10.9%** (YTD -19.9%, 3-mo -10.6%). The shares are down 10.9% over twelve months including dividends.
- **From 52-week high: -25.0%** (15.9% above the low). Trading 25% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 44**. An RSI of 44 is neutral.
- **Beta (1 yr): 0.77** (volatility 41%). Beta of 0.77 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PTCT · Page: https://foliofundamentals.com/stocks/ptct

Not investment advice.